The Anti-Inflammatory Power in Cannabis Comes From THCA, Not CBD, for Colon Disease

The anti-inflammatory activity of cannabis extracts on colon cells came from THCA (the raw, unheated form of THC), not from CBD, and worked through the GPR55 receptor rather than classical cannabinoid receptors.

Nallathambi, Rameshprabu et al.·Cannabis and cannabinoid research·2017·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-01463Animal StudyPreliminary Evidence2017RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

This study systematically characterized which components of cannabis extracts produce anti-inflammatory effects in colon models relevant to inflammatory bowel disease.

The anti-inflammatory activity was traced to a specific fraction containing delta-9-tetrahydrocannabinolic acid (THCA), the raw precursor to THC found in unheated cannabis. THCA reduced interleukin-8 (a key inflammatory marker) in both colon cell lines and in tissue biopsies from IBD patients.

The effects were mediated at least partially through the GPR55 receptor, not the classical CB1 or CB2 cannabinoid receptors. A GPR55 antagonist significantly reduced the anti-inflammatory activity, while a CB2 antagonist affected cell proliferation rather than inflammation.

CBD showed a different pattern: it had dose-dependent cytotoxic (cell-killing) activity, but its anti-inflammatory activity occurred only at low concentrations and in a bell-shaped manner (effective at low doses, ineffective at higher ones).

The authors concluded that for non-psychoactive IBD treatment, THCA should be preferred over CBD.

Key Numbers

THCA in fraction 7 was the primary anti-inflammatory component. GPR55 antagonist significantly reduced anti-inflammatory activity. CBD showed bell-shaped anti-inflammatory response (effective only at low concentrations). Results confirmed in IBD patient tissue biopsies.

How They Did This

Cannabis flowers were extracted with ethanol and fractionated. Anti-inflammatory activity was tested on three epithelial cell lines and colon tissue biopsies from IBD patients. Chemical analysis used HPLC, mass spectrometry, and NMR. Gene expression of COX2 and MMP9 was measured by qRT-PCR. Receptor involvement was tested using specific antagonists.

Why This Research Matters

This study redirects the focus of cannabis-based IBD therapy from CBD (which showed limited anti-inflammatory activity) to THCA (which was highly effective). Since THCA is non-psychoactive (it has not been heated/decarboxylated into THC), it could provide anti-inflammatory benefits without the high.

The Bigger Picture

This finding challenges the popular focus on CBD for inflammatory conditions and highlights THCA as a potentially superior anti-inflammatory cannabinoid for gut disease. The involvement of GPR55 rather than CB1/CB2 receptors opens new pharmacological targets.

What This Study Doesn't Tell Us

In vitro and ex vivo study; clinical effects in patients have not been tested. The extract fractionation process may not reflect whole-plant cannabis effects. THCA stability (it converts to THC with heat) creates formulation challenges for clinical use.

Questions This Raises

  • ?Could THCA-rich preparations be developed as non-psychoactive IBD treatments?
  • ?Would oral THCA survive stomach acid and reach the colon intact?
  • ?How does GPR55 signaling in the gut mediate anti-inflammatory effects?

Trust & Context

Key Stat:
THCA, not CBD, was the primary anti-inflammatory compound in cannabis for colon inflammation
Evidence Grade:
In vitro and ex vivo study with systematic fractionation and receptor characterization. Preliminary because clinical effects have not been tested.
Study Age:
Published in 2017.
Original Title:
Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts.
Published In:
Cannabis and cannabinoid research, 2(1), 167-182 (2017)
Database ID:
RTHC-01463

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Is CBD or THC better for gut inflammation?

This study found that THCA (the raw, unheated form of THC) was the primary anti-inflammatory compound for colon cells, while CBD had limited anti-inflammatory effects. Since THCA is non-psychoactive, it could provide benefits without getting you high.

What is THCA?

THCA (tetrahydrocannabinolic acid) is the raw precursor to THC found in unheated cannabis. When you heat cannabis, THCA converts to THC. THCA itself is not psychoactive but this study found it has strong anti-inflammatory properties for the gut.

Read More on RethinkTHC

Cite This Study

RTHC-01463·https://rethinkthc.com/research/RTHC-01463

APA

Nallathambi, Rameshprabu; Mazuz, Moran; Ion, Aurel; Selvaraj, Gopinath; Weininger, Smadar; Fridlender, Marcelo; Nasser, Ahmad; Sagee, Oded; Kumari, Puja; Nemichenizer, Diana; Mendelovitz, Maayan; Firstein, Nave; Hanin, Orly; Konikoff, Fred; Kapulnik, Yoram; Naftali, Timna; Koltai, Hinanit. (2017). Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts.. Cannabis and cannabinoid research, 2(1), 167-182. https://doi.org/10.1089/can.2017.0027

MLA

Nallathambi, Rameshprabu, et al. "Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts.." Cannabis and cannabinoid research, 2017. https://doi.org/10.1089/can.2017.0027

RethinkTHC

RethinkTHC Research Database. "Anti-Inflammatory Activity in Colon Models Is Derived from Δ..." RTHC-01463. Retrieved from https://rethinkthc.com/research/nallathambi-2017-antiinflammatory-activity-in-colon

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.